Royal DSM N.V., The Netherlands, introduced a new company brand - Bright Science. Brighter Living. - to better symbolize the transition from a chemical company into a life, sciences and materials sciences company active in health, nutrition and materials.
The new brand is a reflection of the overall positioning of the company. It stands for the DSM strategy, culture and the way it wants its employees to work together. The brand also represents the company’s sustainability value (working with a triple bottom line of people, planet and profit thereby creating value for all stakeholders), its philosophy (based on the realization that DSM can only fulfill its strategic goals if it operates as one united team across the globe) and it fits with the mission to create brighter lives for people today and for generations to come.
“With the portfolio restructuring completed, with our new strategy that focuses on growth, with the culture change on the road and with our “One” DSM philosophy, this is the time to mark the new DSM, internally and externally,” says Feike Sijbesma, chairman and CEO of the managing board.
The new DSM is summed up by the new tagline: Bright Science. Brighter Living. DSM uses its science and innovation in partnership with its customers to create products and solutions that make a positive difference to people lives. Next to the new tagline comes a new logo, which conveys brightness as the mix and overlay of colors represents the diversity of DSM people and the unique combination of DSM global talents and technologies, working together to create innovative and sustainable solutions in a variety of businesses (nutrition, health and materials). The logo also showcases dynamic motion, a sense of movement because the company is constantly looking to evolve in an ever-changing world and has great track record in doing so.
Meanwhile, DSM completed the subsequent offering period to its all-cash tender offer to purchase all of the outstanding shares of common stock of Martek Biosciences Corp., Columbia, Md., at a price of $31.50 per share.
The depositary for the tender offer advised that a total of approximately 262,000 additional Martek shares of common stock had been validly tendered in the subsequent offering period, which, together with the shares validly tendered and not withdrawn during the initial offering period, resulted in DSM holding approximately 89.5% of Martek’s currently outstanding shares. DSM has accepted payment for all validly tendered shares.
DSM says it intends to exercise the top-up option that was granted to the merger agreement to purchase additional shares directly from Martek and to complete a short-form merger in accordance with the merger agreement. In the short-form merger, Greenback Acquisition Corp., an indirect wholly-owned subsidiary of Koninklijke DSM N.V., will be merged with and into Martek, and each share of Martek common stock not tendered in the tender offer, other than those as to which holders exercise appraisal rights under Delaware law and those held by DSM or Martek or their respective subsidiaries, will be converted in the merger into the right to receive $31.50 per share in cash, without interest and less any required withholding taxes. This is the same price per share paid in the tender offer.
For more information on Martek Biosciences, visit www.martek.com. For more information on DSM, go to www.dsm.com